MARKET

FGEN

FGEN

FibroGen
NASDAQ

Real-time Quotes | Nasdaq Last Sale

45.49
-0.27
-0.59%
After Hours: 45.73 +0.24 +0.52% 16:11 10/20 EDT
OPEN
46.47
PREV CLOSE
45.76
HIGH
46.97
LOW
45.21
VOLUME
421.68K
TURNOVER
--
52 WEEK HIGH
51.56
52 WEEK LOW
22.65
MARKET CAP
4.11B
P/E (TTM)
-12.8405
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
FibroGen to Present New Efficacy and Safety Analyses from Roxadustat Global Phase 3 Program at American Society of Nephrology Kidney Week 2020 Reimagined
Late-breaking abstracts explore cardiovascular outcomes of patients with anemia in chronic kidney disease (CKD) treated with roxadustat, including associations with achieved hemoglobin levels and risk of Major Adverse
Benzinga · 6d ago
New Ventures Funds Rebrands as Scientia Ventures
New Ventures Funds has launched a new corporate brand identity and changed its name to Scientia Ventures. The new website for the firm can be found at: www.scientiavc.com. This reflects the broadening of the firm's strategic direction since launching its 3rd fund in 2017 to reflect its focus on transformational
PR Newswire · 10/02 11:00
Hedge Funds Have Never Been More Bullish On FibroGen Inc (FGEN)
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the second quarter. You can find articles about an
Insider Monkey · 09/29 22:22
The Pandemic Speeds Up the Health-Care Revolution
The drive to quickly conquer Covid-19 has accelerated innovation across the health-care sector. Barron’s roundtable experts highlight the most promising...
marketwatch.com · 09/26 00:37
FibroGen (FGEN) Investor Presentation - Slideshow
The following slide deck was published by FibroGen, Inc. in conjunction with this event.
Seekingalpha · 09/18 17:39
Market Sentiment Around Loss-Making FibroGen, Inc. (NASDAQ:FGEN)
We feel now is a pretty good time to analyse FibroGen, Inc.'s (NASDAQ:FGEN) business as it appears the company may be...
Simply Wall St. · 09/15 12:31
The Daily Biotech Pulse: AbbVie In-licenses I-Mab's Cancer Drug, Savara Pulls The Plug On Cystic Fibrosis Study
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 3)
Benzinga · 09/04 11:28
Akebia's vadadustat pain is FibroGen's gain, up 15%
FibroGen (FGEN) is up 15% premarket on average volume in apparent response to the selloff in Akebia Therapeutics (AKBA) after it reported that two late-studies evaluating vadadustat in non-dialysis patients with CKD
Seekingalpha · 09/03 13:18
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of FGEN. Analyze the recent business situations of FibroGen through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average FGEN stock price target is 62.75 with a high estimate of 90.00 and a low estimate of 44.00.
EPS
Institutional Holdings
Institutions: 301
Institutional Holdings: 70.68M
% Owned: 78.23%
Shares Outstanding: 90.36M
TypeInstitutionsShares
Increased
81
7.97M
New
53
-477.58K
Decreased
53
4.92M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.98%
Pharmaceuticals & Medical Research
-0.26%
Key Executives
Chairman/Director
James Schoeneck
Chief Executive Officer/Director
Enrique Conterno
Chief Financial Officer
Pat Cotroneo
Other
K. Peony Yu
Senior Vice President
Christine Chung
Senior Vice President
Elias Kouchakji
Other
Percy Carter
Other
Thane Wettig
Other
Kin-Hung Yu
Lead Director/Independent Director
Thomas Kearns
Director
Aoife Brennan
Director
Benjamin Cravatt
Independent Director
Suzanne Blaug
Independent Director
Jeffrey Edwards
Independent Director
Jeffrey Henderson
Independent Director
Maykin Ho
Independent Director
Kalevi Kurkijarvi
Independent Director
Gerald Lema
Independent Director
Rory Riggs
Independent Director
Toshinari Tamura
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About FGEN
FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company’s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of FibroGen Inc stock information, including NASDAQ:FGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FGEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FGEN stock methods without spending real money on the virtual paper trading platform.